20 articles with Alvotech
Alvotech today welcomed the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of Alvotech‘s high-concentration AVT02 (100 mg/mL), a proposed biosimilar to Humira® (adalimumab).
Alvotech today announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study (AVT04-GL-301) for AVT04.
Alvotech Holdings SA announced that it has entered into an amendment and restatement agreement with bondholders of its $300m covertible bond issued on December 14, 2018.
Alvotech Seeks to End AbbVie’s Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.
Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold as Humira.
AbbVie has filed a legal complaint against Icelandic pharmaceutical company Alvotech for the latter’s alleged misappropriation of trade secrets involving the development of a generic version of AbbVie’s rheumatoid arthritis drug Humira.
Biopharmaceutical company Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million.
Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China
Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient access to high quality biosimilars in China°
Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab) Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms AVT02 is highly similar to its reference product in terms of structure and function The pharmacokinetic (PK) similarity study for AVT02 (AVT02-GL-101) has met its primary objectives
Biopharmaceutical company Alvotech announced that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round.
The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry
JAMP Pharma Group signs a landmark partnership agreement for the commercialization of five biosimilar medicines in Canada
Canadian pharmaceutical company JAMP Pharma Group has signed an exclusive agreement with global speciality biopharmaceutical company Alvotech for the Canadian commercial rights to five biosimilars.
Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG announced that they have entered into an exclusive strategic partnership for the commercialization of seven biosimilars in all key European markets and selected markets outside Europe.
Biopharmaceutical company Alvotech announced that Abu Dhabi-based investment company, Yas Holding, has acquired a 2.5% stake in their business and signed an agreement for the exclusive partnership and supply of three Alvotech biosimilar candidates, which Yas Holding will commercialize in the MENA region.
Biopharmaceutical company to unify quality management on a single platform for greater efficiency and compliance
Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors
Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan.